<ul><li>Eindhoven-based Salvia BioElectronics raised €53 million in a Series B financing round for its neuromodulation therapy targeting chronic migraine.</li><li>The round was led by Innovation Industries, with participation from other investors to bring MySalvia Therapy to patients in need.</li><li>The therapy features ultra-thin implants for targeted stimulation to reduce frequency and intensity of migraine attacks.</li><li>Salvia aims to obtain regulatory approvals and commercialize the therapy to provide relief for millions affected by chronic migraine.</li></ul>

Migraines? This Dutch startup just raised €53 million to transform migraine treatment with its ultra-thin implant

Discover more